# A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

> **NCT03174353** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 114 (actual)

## Conditions studied

- Pancreatic Leak
- Pancreatic Fistula
- Pancreaticoduodenal; Fistula
- Pancreatectomy; Hyperglycemia

## Interventions

- **DRUG:** Lanreotide Prefilled Syringe

## Key facts

- **NCT ID:** NCT03174353
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2022-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174353, "A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03174353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*